Steroid hormone withdrawal syndromes: Pathophysiology and clinical significance

Urologic Clinics of North America

Volumn 24, Issue 2, 1997, Pages 421-431

  Kelly, W K ^a   Slovin, S ^a   Scher, H I ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; BICALUTAMIDE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN DERIVATIVE; HYDROCORTISONE; MEGESTROL ACETATE; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID; STEROID HORMONE; SURAMIN;

CANCER HORMONE THERAPY; CASTRATION; CLINICAL TRIAL; DNA SEQUENCE; DRUG WITHDRAWAL; HUMAN; LIVER METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW;

EID: 0030929675     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70389-X     Document Type: Article

References (47)

1. K. Akakura S. Akimoto T. Ohki Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate Urology 1995 in press
2. N.K. Bissada A.T. Kaczmarek Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbesterol J Urol 153 1995 1944 1945
3. M. Castagnaro D.W. Yandell B. Dockhorn Dworniczak [Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer] Verh Dtsch Ges Pathol 77 1993 119 123
4. M.P. Collinson F. Daniel C.J. Tyrell Response of carcinoma of the prostate to withdrawal of flutamide Br J Urol 72 1993 662 663
5. Z. Culig H. Klocker J. Eberle DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction Prostate 22 1993 11 22
6. N.A. Dawson D.G. McLoed Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome J Urol 153 1995 1946 1947
7. N.A. Dawson M.R. Cooper W.D. Figg Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables Cancer 76 1996 453 462
8. J.R. Drago R.J. Santen A. Lipton Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma Cancer 53 1984 1447 1450
9. A. Dupont J. Gomez L. Cusan Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy J Urol 150 1993 908 913
10. M.A. Eisenberger L.M. Reyno D.I. Jodrell Suramin, an active drug for prostate cancer: Interim observations in a phase I trial J Natl Cancer Inst 85 1993 611 621
11. M.A. Ferro D. Gillatt M.O. Symes High-dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of prostate-specific antigen to monitor response Urology 34 1989 134 138
12. W.D. Figg O. Sartor M.R. Cooper Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer Am J Med 98 1995 412 414
13. W.D. Figg A.O. Sartor A. Thibault The in vitro response of four antisteroid receptor agents on the hormone responsive prostate cancer cell line LNCaP Proceedings of the American Association for Cancer Research 35 1994 1629
14. S.D. Fossa G. Hosbach E. Paus Flutamide in hormone-resistant prostatic cancer J Urol 144 1990 1411 1414
15. J.P. Gaddipati D.G. McLeod H.B. Heidenberg Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers Cancer Res 54 1994 2861 2864
16. J. Herrada P. Dieringer C.J. Logothetis Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal J Urol 155 1996 620 623
17. A. Howell D.J. Dodwell H. Anderson Response after withdrawal of tamoxifen and progestens in advanced breast cancer Ann Oncol 3 1992 611 617
18. C. Huggins C.V. Hodges Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
19. W.K. Kelly H.I. Scher Prostate specific antigen decline after antiandrogen withdrawal J Urol 149 1993 607 609
20. W.K. Kelly T. Curley C. Liebertz Phase II trial of 13-cis retinoic acid and interferon-alpha 2a in patients with adenocarcinoma of the prostate [abstract] Proceedings of the American Society of Clinical Oncology 15 1996 254
21. W.K. Kelly T. Curley C. Leibertz Prospective evaluation of hydrocortisone and suramin J Clin Oncol 13 1995 2208 2213
22. F. Labrie A. Belanger J. Simard Combination therapy for prostate cancer: Endocrine and biologic basis for its choice as new standard first-line therapy [abstract] Cancer 71 1993 1059
23. A. Manni M. Bartholomew R. Caplan Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome J Clin Oncol 6 1988 1456 1466
24. Mohler JL, Sharief Y, El-Awady M, et al: Do androgen receptor gene mutations have a role in androgen independent prostatic carcinoma? Presented at the Society for Basic Urologic Research, San Antonio, 1993.
25. C. Myers M. Cooper C. Stein Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol 10 1992 881 889
26. D.W. Newling L. Dennis K. Vermeylen Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer Cancer Supplement 72 suppl 1993 3793 3798
27. J.R. Newmark E.O. Hardy D.C. Tonb Androgen receptor gene mutations in human prostate cancer Proc Natl Acad Sci U S A 89 1992 6319 6323
28. P.T. Nieh Withdrawal phenomenon with the antiandrogen casodex J Urol 153 1995 1070 1073
29. J.A. Ruizeveld de Winter P.J. Janssen H.M. Sleddens Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer Am J Pathol 144 1994 735 746
30. M.V. Sadi P.C. Walsh E.R. Barrack Immunohistochemical study of androgen receptors in metastatic prostate cancer: Comparison of receptor content and response to hormonal therapy Cancer 67 1991 3057 3064
31. O. Sartor M. Cooper M. Weinberger Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer J Natl Cancer Inst 86 1994 222 227
32. H.I. Scher W.K. Kelly The flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostatic cancer J Clin Oncol 11 1993 1566 1572
33. H.I. Scher M. Mazumdar W.K. Kelly Clinical trials in relapsed prostate cancer: Defining the target J Natl Cancer Inst 88 1996 1623 1633
34. H.I. Scher G. Steineck W.K. Kelly Hormone-refractory (“D3”) prostate cancer: Refining the concept Urology 46 1995 142 148
35. H.I. Scher Z.-F. Zhang L. Cohen W.K. Kelly Hormonally relapsed prostatic cancer: Lessons from the flutamide withdrawal syndrome Advances in Urology 8 1995 61 95
36. M.P. Schoenberg J.M. Hakami S. Wang Microsatellite mutation (CAG24→18) in the androgen receptor gene in human prostate cancer Proceedings of the American Society of Clinical Oncology 35 1994 277
37. E.J. Small P.R. Carroll Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome Urology 43 1994 408 410
38. E.J. Small S. Srinivas The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer Cancer 76 1995 1428 1434
39. E.J. Small P. Schellhammer G. Venner A double-blind assessment of antiandrogen withdrawal from casodex (C) or eulexin (E) therapy while continuing luteinizing hormone releasing hormone analogue (LHRH-a) therapy for patients with stage d2 prostate cancer [abstract] Proc Am Soc Clin Oncol 15 1996 255
40. H. Suzuki N. Sato Y. Watabe Androgen receptor gene mutations in human prostate cancer J Steroid Biochem Mol Biol 46 1993 759 765
41. M.E. Taplin G.J. Bybley T.D. Shuster Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 1995 1393 1398
42. C.D. Taylor P. Elson D.L. Trump Importance of continued testicular suppression in hormone-refractory prostate cancer J Clin Oncol 11 1993 2167 2172
43. W.D. Tilley G. Buchanan T.E. Hickey Detection of androgen receptor gene mutations in human prostate cancers by immunohistochemistry and PCR-SSP [abstract] Proc Amer Assoc Cancer Res 36 1995 266
44. W.D. Tilley G. Buchanan T.E. Hickey Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen-independence Clin Cancer Res 2 1996 277 285
45. J. Veldscholte C. Ris-Stalpers G.G.J.M. Kuiper A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem Biophys Res Commun 173 1990 534 543
46. T. Visakorpi E. Hyytinen P. Koivisto In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat Genet 9 1995 401 406
47. G. Williams D.J. Kerle H. Ware Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer Br J Urol 58 1986 45 51